Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin XR in myelofibrosis
RBR-5g38dtPhase 2Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF), sponsored by Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Primary endpoint: Primary drug response by spleen volume reduction. Started Oct 2019; status: recruiting.
02
Drugs
metformin
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on RBR-5g38dt.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5g38dt.